Stryker Corporation (NYSE:SYK) Given Consensus Rating of “Moderate Buy” by Analysts

Stryker Corporation (NYSE:SYK) has received a consensus rating of “Moderate Buy” from the nineteen ratings firms that are covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $434.3684.

Several brokerages recently commented on SYK. Wells Fargo & Company boosted their price target on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Barclays boosted their target price on shares of Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Truist Financial raised their price target on shares of Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a report on Friday, November 14th. Redburn Partners set a $420.00 price objective on shares of Stryker in a report on Thursday, September 18th. Finally, Rothschild & Co Redburn assumed coverage on Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 target price on the stock.

Stryker Trading Down 0.2%

NYSE:SYK opened at $359.53 on Wednesday. The stock has a market cap of $137.49 billion, a PE ratio of 47.62, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. Stryker has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The stock’s 50-day moving average is $370.62 and its two-hundred day moving average is $381.03.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same period last year, the company earned $2.87 earnings per share. Stryker’s quarterly revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, equities research analysts forecast that Stryker will post 13.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction on Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the sale, the chief accounting officer directly owned 2,833 shares in the company, valued at approximately $1,035,433.17. The trade was a 40.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 522,453 shares of company stock worth $185,516,867. 5.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stryker

Hedge funds have recently bought and sold shares of the company. Norges Bank acquired a new stake in Stryker in the 2nd quarter valued at approximately $1,882,173,000. Alliancebernstein L.P. increased its position in Stryker by 307.6% during the second quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock worth $2,214,146,000 after acquiring an additional 4,223,366 shares during the period. Nuveen LLC acquired a new position in Stryker during the 1st quarter valued at $558,075,000. Corient Private Wealth LLC boosted its holdings in Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after purchasing an additional 1,146,998 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after purchasing an additional 1,021,496 shares during the period. 77.09% of the stock is currently owned by institutional investors.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.